Prilenia Collaborates with CHDI Foundation to Enhance Huntington's Disease Research
Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research
Image: Businesswire
Prilenia Therapeutics has signed a Data Use Agreement with the CHDI Foundation to provide clinical trial data from its PRIDE and PROOF studies. This collaboration aims to improve research on Huntington's disease (HD) treatments, enhancing understanding of placebo effects and supporting the development of effective therapies.
- 01Prilenia will share clinical trial data from placebo arms of its PRIDE and PROOF studies with the CHDI Foundation.
- 02The agreement allows CHDI to use the data for research while retaining ownership of any results generated.
- 03Huntington's disease affects approximately 100,000 people globally, with 300,000 at risk.
- 04Prilenia aims to develop transformative medicines for neurodegenerative diseases, including HD and ALS.
- 05The only current treatments for HD focus on symptomatic relief, with no impact on disease progression.
Advertisement
In-Article Ad
Prilenia Therapeutics B.V. has announced a Data Use Agreement with the CHDI Foundation, enabling the sharing of clinical trial data from the placebo arms of its PRIDE and PROOF studies. This initiative aims to advance research into Huntington's disease (HD) by enhancing understanding of placebo effects, which could improve future clinical trial designs and outcomes. Dr. Michael R. Hayden, CEO of Prilenia, emphasized the importance of collaboration in utilizing high-quality data for innovation in HD treatment. The agreement grants CHDI a worldwide, non-exclusive license to the data, while Prilenia retains ownership of the underlying data, ensuring participant anonymity. Huntington's disease is a rare, inherited neurodegenerative disorder affecting around 100,000 individuals worldwide, with an additional 300,000 at risk. Currently, treatments only provide symptomatic relief, highlighting the urgent need for effective therapies. Prilenia is committed to developing transformative medicines for neurodegenerative disorders and is partnered with Ferrer for the commercialization of its lead compound, pridopidine.
Advertisement
In-Article Ad
The collaboration is expected to accelerate research and development of effective treatments for Huntington's disease, potentially benefiting thousands of patients.
Advertisement
In-Article Ad
Reader Poll
How do you feel about the collaboration between Prilenia and CHDI Foundation for Huntington's disease research?
Connecting to poll...
Read the original article
Visit the source for the complete story.